Monomethyl Auristatin F (MMAF, CAS: 745017-94-1)
MMAF is a synthetic microtubule inhibitor derived from dolastatin 10, widely used in antibody-drug conjugates (ADCs) for targeted cancer therapy. It disrupts microtubules, halts cell division, and induces apoptosis in cancer cells, offering precise and effective treatment.
Key Features:
- Microtubule Inhibitor: Blocks tubulin polymerization, stopping cancer cell division.
- Selective Targeting: Targets cancer cells.
- Proven Efficacy: Used in FDA-approved ADCs like Blenrep and Polivy.
- Stability: Designed from dolastatin 10 for enhanced performance.
MMAF Applications:
- Antibody-Drug Conjugates (ADCs):
- Delivers cytotoxic drugs directly to cancer cells.
- Improves specificity and reduces side effects.
- Cancer Therapy Research:
- Crucial for developing advanced cancer treatments.
- Targets cancers with overexpressed antigens.
- Clinical Studies:
- Supports new ADC research.
- Assesses therapeutic potential in various cancer models.
Ref:
Smith LM, Nesterova A, Alley SC, Torgov MY, Carter PY. Potent cytotoxicity of an auristatin-containing antibody-drug conjugate targeting melanoma cells expressing melanotransferrin/p97. Mol Cancer Ther June 2006 5; 1474-82.
Dosio F, Brusa P, Cattel L. Immunotoxins and anticancer drug conjugate assemblies: the role of the linkage between components. Toxins (Basel). 2011;3(7):848-883.
Monomethyl auristatin E (Wikipedia)
AxisPharm offers 5000+ PEG Linkers with high purity. Different kinds of PEG Reagents may be available by custom synthesis.
